rosR, a Determinant of Nodulation Competitiveness in Rhizobium etli

Autor: Mark A. Bittinger, Jocelyn L. Milner, Barry J. Saville, Jo Handelsman

Publikováno v: Molecular Plant-Microbe Interactions, Vol 10, Iss 2, Pp 180-186 (1997)

We previously described a Tn5 mutant of Rhizobium etli strain CE3, designated CE3003, that is decreased in nodulation competitiveness, reduced in competitive growth in the rhizosphere, and has a hydrophobic cell surface (R. S. Araujo, E. A. Robleto,

Externí odkaz: https://doaj.org/article/a33f2c7d853a4b0d88577748b0563501

Data from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Autor: Matthew V. Lorenzi, Raluca I. Verona, Kwok-Kin Wong, Christopher Moy, Pasi A. Janne, Kathryn Packman, Paul T. Kirschmeier, Mark A. Bittinger, Sylvie Laquerre, Catherine Sanders, Julie A. Rytlewski, Andrew H. Beck, Aditya Khosla, Jessie M. English, Catherine Ferrante, Elena Ivanova, Samuel N. Regan, Dyane Bailey, Martha R. Gowaski, Kristin DePeaux, Abha Dhaneshwar, Jeffrey Liu, Dennis M. Bonal, Wei Huang, Enrique Zudaire, Sima J. Zacharek, Mari Kuraguchi, Sangeetha Palakurthi

The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We hypothesized that combining targeted therapy with immune modulation would show enhanced antitumor re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ef82160a04751b2f6d5b28b394c18e
https://doi.org/10.1158/2326-6066.c.6550248

Data from Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors

Autor: Raphael Bueno, Kwok-Kin Wong, Peter S. Hammerman, Lynette M. Sholl, Pasi A. Jänne, Kai W. Wucherpfennig, F. Stephen Hodi, Scott J. Rodig, Adam J. Bass, David A. Barbie, William G. Richards, Julianne Barlow, Jessie M. English, Christina Almonte, Shohei Koyama, Lauren Keogh, Mark A. Bittinger, Abigail A. Santos, Xiaoyun Liao, Grit S. Herter-Sprie, Meghana Kulkarni, Elena V. Ivanova, Patrick H. Lizotte, Hongye Liu, Robert E. Jones, Mark M. Awad

PD-L1 immunohistochemical staining does not always predict whether a cancer will respond to treatment with PD-1 inhibitors. We sought to characterize immune cell infiltrates and the expression of T-cell inhibitor markers in PD-L1–positive and PD-L1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::969115837501efc52aa2af781bec38a1
https://doi.org/10.1158/2326-6066.c.6548897.v1

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Autor: Paul Kirschmeier, Jeffrey Liu, Andrew H. Beck, Catherine Ferrante, Sangeetha Palakurthi, Christopher Moy, Elena Ivanova, Mark A. Bittinger, Martha R. Gowaski, Abha Dhaneshwar, Dennis M. Bonal, Mari Kuraguchi, Matthew V. Lorenzi, Kwok-Kin Wong, Kristin Depeaux, Samuel N. Regan, Jessie M. English, Catherine Sanders, Raluca I. Verona, Julie A. Rytlewski, Pasi A. Jänne, Kathryn Packman, Dyane Bailey, Enrique Zudaire, Wei Huang, Sima Zacharek, Sylvie Laquerre, Aditya Khosla

Publikováno v: Cancer Immunology Research. 7:1457-1471

The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We hypothesized that combining targeted therapy with immune modulation would show enhanced antitumor re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2c1f9a01b11be87cfe0da00f9655a0
https://doi.org/10.1158/2326-6066.cir-18-0595

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Autor: Mark A. Bittinger, Parin Shah, William F. Walker, Meng Xiao He, Nicole R. LeBoeuf, Chaoran Cheng, Rohit Thummalapalli, Chandrasekar Venkataramani, Glenn J. Hanna, Joshua A. Kaplan, Eliezer M. Van Allen, Jochen H. Lorch, Susanna Stinson, Raphael Bueno, Max M. Quinn, Michaela Bowden, Genevieve M. Boland, Cloud P. Paweletz, Bart Phillips, Gao Zhang, Jong Wook Kim, Adriano Piris, Patrick H. Lizotte, Raven Vlahos, Patrick A. Ott, Lance Stapleton, Levi A. Garraway, Hua Zhang, Chensheng W. Zhou, Jean Pierre Eliane, Eric S. Wang, Alicia Smart, Andrew Portell, Zhi Wei, Hongye Liu, Jiehui Deng, Meenhard Herlyn, Shuai Li, Diana Miao, Israel Cañadas, F. Stephen Hodi, Hans Vitzthum, Marc R. Hammond, Russell W. Jenkins, Prafulla C. Gokhale, Thanh U. Barbie, Michal Barzily-Rokni, David A. Barbie, Keith T. Flaherty, Tran C. Thai, Shunsuke Kitajima, Gordon J. Freeman, Roger D. Kamm, Juan J. Miret, Lauren Keogh, Elena Ivanova, Charles H. Yoon, Lisa A. Cameron, Viswanath Gunda, Ashley A. Merlino, David Dornan, Anat Stemmer-Rachamimov, Joshua A. Wong, Kwok-Kin Wong, William G. Richards, Sangeetha Palakurthi, Maria Anguiano, Wei Huang, Sareh Parangi, James M. Cleary, Benjamin Izar, Amir Reza Aref, Brian C. Miller, Vivek Sivathanu, Zhiheng Jia, Asaf Rotem, Mai P. Hoang, Paul Kirschmeier, Benchun Miao, Mei-Ju Su, Manisha Thakuria, Tian Tian, Robert E. Jones, Guilherme Rabinowits

Publikováno v: Cancer Discovery. 8:196-215

Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Her

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c6bd16a471cf8026945da91f5ec6b25
https://doi.org/10.1158/2159-8290.cd-17-0833